CA
NZ
UK
AU
IND
US
…
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Elicio Therapeutics Inc. is a clinical-stage biotechnology company focused on developing immune-modulating therapies for cancer and other diseases, though publicly available disclosures about its pipeline and platforms are limited. Long-term growth may be driven by clinical trial progress, regulatory milestones, strategic partnerships and successful commercialization of any approved therapies, so investors may find the company attractive for exposure to oncology immunotherapy development with upside tied to R&D outcomes.
The principal investment risks include binary clinical and regulatory outcomes, an ongoing need for external capital and potential dilution, competitive pressure from larger oncology developers, and the operational and execution risks typical of clinical-stage biotechs.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -39.57M | -51.90M | -35.20M | -28.21M | -26.40M |
| Net income | -39.57M | -51.90M | -35.20M | -28.21M | -26.40M |
| Selling general administrative | 12.81M | 11.33M | 11.90M | 5.63M | 7.54M |
| Gross profit | -1.13M | -1.18M | -1.17M | - | - |
| Reconciled depreciation | 1.13M | 1.18M | 1.17M | 0.39M | 0.25M |
| Ebit | -37.71M | -51.44M | -34.14M | -23.67M | -25.47M |
| Ebitda | -36.59M | -50.27M | -32.97M | -23.28M | -25.22M |
| Depreciation and amortization | 1.13M | 1.18M | 1.17M | 0.39M | 0.25M |
| Operating income | -37.71M | -44.99M | -35.74M | -23.73M | -25.47M |
| Other operating expenses | 37.71M | 44.99M | 35.74M | 23.73M | 25.47M |
| Interest expense | 1.13M | 0.46M | 1.06M | 3.60M | 0.88M |
| Tax provision | 0.00M | 0.00M | 0.00M | - | - |
| Interest income | 0.78M | 0.78M | 0.37M | 0.06M | 0.00M |
| Net interest income | -0.36M | -3.18M | -0.69M | -3.53M | -0.87M |
| Income tax expense | - | - | - | 3.60M | 0.88M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 36.59M | 43.81M | 34.58M | 23.73M | 25.47M |
| Cost of revenue | 1.13M | 1.18M | 1.17M | - | - |
| Total other income expense net | -1.86M | -6.91M | 0.55M | -0.94M | -0.05M |
| Net income from continuing ops | -39.57M | -51.90M | -35.20M | -28.21M | -26.40M |
| Net income applicable to common shares | - | - | - | -28.21M | -26.40M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 25.86M | 28.18M | 27.15M | 22.66M | 14.81M |
| Other current assets | 0.75M | 3.08M | 0.17M | 0.04M | 0.09M |
| Total liab | 24.23M | 39.49M | 15.77M | 124.81M | 89.35M |
| Total stockholder equity | 1.64M | -11.31M | 11.37M | -102.15M | -74.54M |
| Other current liab | 6.43M | 8.41M | 0.04M | 3.37M | 2.96M |
| Common stock | 0.18M | 0.11M | 0.10M | 0.18M | 0.17M |
| Capital stock | 0.18M | 0.11M | 0.10M | 0.18M | 0.17M |
| Retained earnings | -233.67M | -194.10M | -142.20M | -107.01M | -78.80M |
| Other liab | - | - | - | 0.09M | 0.03M |
| Other assets | - | - | - | 3.45M | -0.00M |
| Cash | 18.56M | 17.62M | 12.89M | 6.16M | 9.28M |
| Total current liabilities | 8.11M | 11.52M | 9.77M | 6.87M | 18.88M |
| Current deferred revenue | - | 1.17M | 4.45M | - | 2.45M |
| Net debt | -4.05M | 8.42M | -5.98M | 1.33M | 2.52M |
| Short term debt | 1.01M | 0.90M | 0.91M | 0.69M | 11.80M |
| Short long term debt | - | - | - | - | 11.80M |
| Short long term debt total | 14.51M | 26.04M | 6.92M | 7.48M | 11.80M |
| Other stockholder equity | 235.26M | 182.85M | 153.68M | 4.69M | 4.09M |
| Property plant equipment | - | - | - | 8.50M | 0.89M |
| Total current assets | 19.31M | 20.69M | 16.35M | 10.72M | 10.36M |
| Net tangible assets | - | - | - | -102.15M | -74.54M |
| Long term debt | 9.41M | 20.03M | - | - | - |
| Accounts payable | 0.67M | 1.04M | 4.37M | 2.81M | 1.68M |
| Accumulated other comprehensive income | -0.13M | -0.17M | -0.20M | - | - |
| Non currrent assets other | 0.77M | 0.60M | 3.52M | 3.45M | 3.57M |
| Non current assets total | 6.55M | 7.49M | 10.80M | 11.95M | 4.46M |
| Capital lease obligations | 5.11M | 6.01M | 6.92M | 7.48M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.08M | -0.03M | -0.65M | -0.53M |
| Change to liabilities | - | - | - | 1.12M | 0.03M |
| Total cashflows from investing activities | -0.02M | -0.08M | -0.03M | -0.65M | -0.53M |
| Net borrowings | 0.00M | 19.73M | 10.00M | - | 14.68M |
| Total cash from financing activities | 36.70M | 42.32M | 38.61M | 21.20M | 19.39M |
| Change to operating activities | - | - | - | -0.61M | 0.84M |
| Net income | -39.57M | -51.90M | -35.20M | -28.21M | -26.40M |
| Change in cash | -0.23M | 5.19M | 5.89M | -1.63M | -5.07M |
| Begin period cash flow | 19.49M | 14.30M | 8.41M | 10.04M | 15.12M |
| End period cash flow | 19.27M | 19.49M | 14.30M | 8.41M | 10.04M |
| Total cash from operating activities | -36.95M | -37.07M | -32.69M | -22.18M | -23.94M |
| Issuance of capital stock | 25.39M | 5.63M | 7.00M | 21.12M | 5.05M |
| Depreciation | 1.13M | 1.18M | 1.17M | 0.39M | 0.25M |
| Other cashflows from investing activities | - | 0.00M | 0.03M | - | - |
| Sale purchase of stock | - | -0.55M | -0.15M | - | - |
| Other cashflows from financing activities | 36.70M | 16.96M | 21.76M | -0.65M | 19.73M |
| Change to netincome | - | - | - | 5.12M | 1.34M |
| Capital expenditures | 0.02M | 0.09M | 0.07M | 0.65M | 0.53M |
| Change in working capital | -3.44M | 3.96M | -0.06M | 0.52M | 0.87M |
| Stock based compensation | 2.70M | 1.45M | 1.18M | 0.58M | 0.62M |
| Other non cash items | 2.24M | 8.24M | 0.21M | 3.60M | 0.67M |
| Free cash flow | -36.97M | -37.16M | -32.76M | -22.83M | -24.46M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| ELTX Elicio Therapeutics Inc. |
-0.06 3.68% |
1.57 | - | - | - | 6.62 | -2.61 |
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert T. Connelly | CEO, President & Director | 1960 |
| Dr. Christopher M. Haqq M.D., Ph.D. | Executive VP, Head of Research & Development and Chief Medical Officer | 1966 |
| Prof. Darrell J. Irvine Ph.D. | Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board | NA |
| Mr. Brian Piekos | Chief Financial Officer | 1975 |
| Mr. Michael DiVecchia | Senior Vice President of Operations & Human Resources | NA |
| Dr. Peter DeMuth Ph.D. | Chief Scientific Officer | 1986 |
| Ms. Megan C. Filoon | General Counsel, Secretary & Compliance Officer | NA |
| Ms. Esther Welkowsky | Senior Vice President of Clinical Development | NA |
| Ms. Joy Seymour | VP & Head of Regulatory Affairs | NA |
| Dr. Thian Kheoh Ph.D. | Senior Vice President of Biometrics | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...